Masitinib for the treatment of Alzheimer's disease: a randomized phase 3 trial

Olivier Hermine, Tengfei Li, Cecile Delarasse, Alain Moussey, Colin Mansfield, Patrice Dubreuil, Grégory Fenaux, Benoit Delatour

Corresponding author: Olivier Hermine MD, PhD. E-mail: ohermine@gmail.com

Introduction

The Rationale for evaluating masitinib in Alzheimer's disease (AD) is based on masitinib's inhibition of the c-KIT, Lyn, Fyn and CSF1R kinases.

Neuroinflammation plays a critical role in AD and mast cells present in the brain play a central role in the inflammatory process. AD is characterized by the loss of blood brain barrier (BBB) integrity. Mast cells participate in the regulation of the BBB's permeability.

Protein tau is phosphorylated by tyrosine kinase Fyn. The proliferation and activation of microglial cells is a hallmark of AD. This mechanism is regulated by the activation CSF1R.

Masitinib targets mast cells by inhibiting c-KIT, Lyn and Fyn. Masitinib inhibits Fyn.

Masitinib inhibits CSF1R and aberrant microglia.

Clinical and Preclinical Data

- Proof of concept for the evaluation of masitinib in AD was established by a phase 2 study. Masitinib showed a consistent improvement of disease in primary (ADAS-cog) and secondary (ADCS-ADL, MMSE) endpoints.
- An ancillary imaging study in mastocytosis has revealed that masitinib is an effective modulator of blood-brain barrier permeability with a concomitant increase in cognitive abilities.
- In vivo proof of concept established via results from an APPxPS1D9 mouse model of AD, indicating improved spatial memory in a curative setting and reduced hippocampal amyloid loads in a preventive setting.
- New evidence shows that masitinib targets proliferating aberrant microglia by inhibiting macrophage colony stimulating factor (CSF1R), a key target for amyotropic lateral sclerosis (ALS), but also a valid target in AD.

("See related oral presentation on Friday, March 11 during the 'Emerging Novel Therapeutic Targets' session")

Overall, these data provide strong medical and biological plausibility for masitinib in the treatment of AD.

Phase 2 of masitinib in mild to moderate AD

Phase 3 (AB09004) – On-going

Objectives

- Phase 2
  - MASITINIB IS AN INNOVATIVE AVENUE OF TREATMENT IN AD
  - Patients with mild to moderate AD
  - Masitinib starting dose of 3 or 6 mg/kg/day
  - Adjunct to cholinesterase inhibitor or memantine
  - 24-week treatment period
  - 34 patients (26 masitinib, 8 placebo)

- Phase 3
  - Effect on ADCS-ADL
  - Effect on ADAS-Cog
  - 3 mg/kg/day
  - 4.5 mg/kg/day
  - 4.5 mg/kg/day with a switch to 6 mg/kg/day

Status: Recruiting

- Study sites are currently open for patient recruitment in 14 countries.

Successful Futility Test

- In February 2015, study AB09004 was assessed as non futile by the Independent Data Monitoring Committee (IDMC)
- Test performed on ADCS-ADL and ADAS-Cog after about one third of the patients were enrolled into the study and had reached the 24 week treatment duration of the study.
- Conclusion: given the data available at that time, study AB09004 is on track to achieve its stated efficacy objective.
- Regular assessments of safety parameters by the IDMC have not revealed any major or unexpected safety concerns.
- Together these assessments suggest that the benefit-risk balance of study AB09004 is positive based on currently available data.

These findings are a significant milestone because to date no other phase 3 study has been reported as non futile in patients with mild to moderate AD.

Pre-planned Interim Analysis

- Planned at around 50% of recruitment
- Anticipated in 2017

For further details of this phase 3 study contact:
investigateurs@ab-science.com

References:

14th International Athens/Synthetic Symposium on Advances in Alzheimer Therapy (March 9 - 12, 2016, Athens, Greece)